Assessment of Luminal and Basal Phenotypes in Bladder Cancer
Assessment of Luminal and Basal Phenotypes in Bladder Cancer
复制标题
DOI：
10.1038/s41598-020-66747-7
复制
发表时间：
2020-06-16
影响因子：
4.6
通讯作者：
Czerniak, Bogdan
中科院分区：
文献类型：
--
作者：
Guo, Charles C.;Bondaruk, Jolanta;Czerniak, Bogdan
基因组分析研究表明，膀胱癌可分为两种分子亚型，称为管腔型和基底型，具有不同的临床行为和对一线化疗的敏感性。我们分析了来自公开可获得的和MD安德森癌症中心队列的膀胱癌肿瘤样品中标志性管腔基因和基础基因的mRNA表达。我们开发了一种称为基底腔过渡（BLT）评分的定量分类器，其以80-94%的灵敏度和83-93%的特异性鉴定膀胱癌的分子亚型。为了便于在初级保健中心对膀胱癌进行分子亚型分型，我们通过免疫组织化学分析了标志性管腔（GATA 3）和基础（KRT 5/6）标志物的蛋白表达，在超过80%的病例中确定了分子亚型。总之，我们提供了一个工具，在常规临床实践中评估膀胱癌的分子亚型。
Genomic profiling studies have demonstrated that bladder cancer can be divided into two molecular subtypes referred to as luminal and basal with distinct clinical behaviors and sensitivities to frontline chemotherapy. We analyzed the mRNA expressions of signature luminal and basal genes in bladder cancer tumor samples from publicly available and MD Anderson Cancer Center cohorts. We developed a quantitative classifier referred to as basal to luminal transition (BLT) score which identified the molecular subtypes of bladder cancer with 80-94% sensitivity and 83-93% specificity. In order to facilitate molecular subtyping of bladder cancer in primary care centers, we analyzed the protein expressions of signature luminal (GATA3) and basal (KRT5/6) markers by immunohistochemistry, which identified molecular subtypes in over 80% of the cases. In conclusion, we provide a tool for assessment of molecular subtypes of bladder cancer in routine clinical practice.